E Gabriela Chiorean

Summary

Affiliation: Indiana University
Country: USA

Publications

  1. ncbi A Phase 1 dose-escalation trial of glufosfamide in combination with gemcitabine in solid tumors including pancreatic adenocarcinoma
    E Gabriela Chiorean
    Indiana University Cancer Center, 535 Barnhill Drive, Room 414, Indianapolis, IN 46202, USA
    Cancer Chemother Pharmacol 61:1019-26. 2008
  2. ncbi A phase 2 trial of glufosfamide in combination with gemcitabine in chemotherapy-naive pancreatic adenocarcinoma
    Elena G Chiorean
    Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN 46202, USA
    Am J Clin Oncol 33:111-6. 2010
  3. ncbi Phase II Trial of Erlotinib and Docetaxel in Advanced and Refractory Hepatocellular and Biliary Cancers: Hoosier Oncology Group GI06-101
    E Gabriela Chiorean
    Indiana University Melvin and Bren Simon Cancer Center, 535 Barnhill Drive, RT473, Indianapolis, Indiana 46202, USA
    Oncologist 17:13. 2012
  4. ncbi A phase I dose escalation and pharmacokinetic study of vatalanib (PTK787/ZK 222584) in combination with paclitaxel in patients with advanced solid tumors
    E Gabriela Chiorean
    Department of Medicine, Indiana University Simon Cancer Center, Indianapolis, IN, USA
    Cancer Chemother Pharmacol 66:441-8. 2010
  5. ncbi A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors
    Christopher J Sweeney
    Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN, USA
    J Clin Oncol 28:4513-20. 2010
  6. ncbi A phase I and pharmacokinetic trial of erlotinib in combination with weekly docetaxel in patients with taxane-naive malignancies
    E Gabriela Chiorean
    Department of Medicine and Biostatistics, Indiana University, Indianapolis, Indiana 46202, USA
    Clin Cancer Res 14:1131-7. 2008

Detail Information

Publications6

  1. ncbi A Phase 1 dose-escalation trial of glufosfamide in combination with gemcitabine in solid tumors including pancreatic adenocarcinoma
    E Gabriela Chiorean
    Indiana University Cancer Center, 535 Barnhill Drive, Room 414, Indianapolis, IN 46202, USA
    Cancer Chemother Pharmacol 61:1019-26. 2008
    ..To evaluate safety and pharmacokinetics and to establish the maximum tolerated dose of glufosfamide when administered in combination with gemcitabine in advanced solid tumors...
  2. ncbi A phase 2 trial of glufosfamide in combination with gemcitabine in chemotherapy-naive pancreatic adenocarcinoma
    Elena G Chiorean
    Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN 46202, USA
    Am J Clin Oncol 33:111-6. 2010
    ..The purpose of this phase II study was to evaluate the safety and efficacy of this combination in chemotherapy-naive pancreatic adenocarcinoma...
  3. ncbi Phase II Trial of Erlotinib and Docetaxel in Advanced and Refractory Hepatocellular and Biliary Cancers: Hoosier Oncology Group GI06-101
    E Gabriela Chiorean
    Indiana University Melvin and Bren Simon Cancer Center, 535 Barnhill Drive, RT473, Indianapolis, Indiana 46202, USA
    Oncologist 17:13. 2012
    ....
  4. ncbi A phase I dose escalation and pharmacokinetic study of vatalanib (PTK787/ZK 222584) in combination with paclitaxel in patients with advanced solid tumors
    E Gabriela Chiorean
    Department of Medicine, Indiana University Simon Cancer Center, Indianapolis, IN, USA
    Cancer Chemother Pharmacol 66:441-8. 2010
    ..To define the maximum-tolerated dose (MTD) for weekly paclitaxel administered in combination with daily vatalanib (PTK787/ZK 222584, PTK/ZK) and assess for a drug-drug interaction...
  5. ncbi A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors
    Christopher J Sweeney
    Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN, USA
    J Clin Oncol 28:4513-20. 2010
    ..This open-label, phase I, dose-escalation study assessed the maximum-tolerated dose (MTD), safety, pharmacokinetics, and antitumor activity of sunitinib in combination with capecitabine in patients with advanced solid tumors...
  6. ncbi A phase I and pharmacokinetic trial of erlotinib in combination with weekly docetaxel in patients with taxane-naive malignancies
    E Gabriela Chiorean
    Department of Medicine and Biostatistics, Indiana University, Indianapolis, Indiana 46202, USA
    Clin Cancer Res 14:1131-7. 2008
    ..This study aimed to define the maximum tolerated dose of weekly docetaxel combined with daily erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor...